LITERATURE REVIEW OPEN ACCESS

Molecular and Immunological Aspects of Crohn's Disease Pathophysiology

Billy Jordan Wrahatnala, Shod Abdurrachman Dzulkarnain, Dini Aulia Cahya

Faculty of Medicine, Universitas Negeri Surabaya, Indonesia

Published: 2025

1. Introduction:

Crohn's Disease (CD) is a chronic inflammatory bowel disease characterized by transmural inflammation that can affect various segments of the gastrointestinal tract, most notably the terminal ileum and colon (1). This condition significantly disrupts the integrity of intestinal tissues, resulting in functional impairments such as malabsorption and diarrhea. A distinguishing feature of CD is segmental inflammation, or "skip lesions," which separates healthy regions from inflamed areas, differentiating it from other inflammatory bowel diseases such as ulcerative colitis (2). The pathophysiology of CD is closely linked to dysregulated immune responses to gut microbiota, leading to chronic inflammation involving various immune cells, such as T helper 1 (Th1), Th17 cells, and innate immune cells like macrophages and neutrophils.

The inflammatory processes in Crohn's Disease induce profound structural changes in intestinal tissues. One of the key manifestations is intestinal wall thickening, driven by immune cell infiltration, new blood vessel formation, and increased mucosal permeability (3). These changes exacerbate nutrient malabsorption, leading to clinical symptoms such as chronic diarrhea, abdominal pain, and weight loss. The inflammatory response also contributes to the formation of non-caseating granulomas, which can appear in various layers of the intestinal wall and serve to isolate antigens or pathogens that cannot be eradicated. Although granulomas help contain infections, their formation can also lead to fibrosis and strictures, further complicating intestinal obstruction (4).

Additionally, transmural inflammation can compromise the structural integrity of the intestinal wall, resulting in the formation of fistulas—abnormal channels connecting different segments of the bowel or linking the intestine to other organs, such as the bladder or vagina. These fistulas often result in severe complications, including abscesses, peritonitis, and intense pain (2). In severe cases, intestinal perforation may occur, potentially leading to life-threatening peritonitis and sepsis if not promptly addressed (5).

Prolonged inflammation in Crohn's Disease also affects the body's nutritional balance, causing malabsorption and nutritional deficiencies. Damage to the intestinal epithelium disrupts the mucosal barrier integrity, increasing intestinal permeability to bacteria and toxins. This exacerbates inflammation, leading to systemic symptoms such as fever, fatigue, and weight loss. Impaired nutrient absorption further deteriorates the patient's condition, highlighting the importance of supportive therapies to improve nutritional recovery (5,6).

The clinical symptoms of Crohn's Disease vary depending on the location and severity of inflammation. In addition to gastrointestinal manifestations such as diarrhea and abdominal pain, patients often experience systemic symptoms like fever and weight loss. Extra-intestinal manifestations, including peripheral arthritis and skin conditions such as erythema nodosum, are also frequently observed, indicating widespread immune involvement. Furthermore, vascular complications, such as deep vein thrombosis, may develop due to chronic inflammation affecting blood coagulation (6).

2. Main Body:

Crohn’s Disease (CD) is a chronic inflammatory bowel disease resulting from dysregulation of the body’s immune response to normal gut microbiota. The pathogenesis of this disease stems from an imbalance in the interaction between the immune system and gut microbiota, leading to chronic transmural inflammation. CD4+ T cells, particularly T helper 1 (Th1) and Th17 cells, play a critical role in this process by producing pro-inflammatory cytokines, such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17) (7,8). Activation of these cells triggers an excessive immune response, resulting in intestinal tissue damage. For instance, Th1 cells promote the production of cytokines like tumor necrosis factor-alpha (TNF-α), which increases intestinal wall permeability and recruits macrophages and neutrophils to sites of inflammation. Similarly, Th17 cells, producing IL-17, exacerbate neutrophil recruitment, intensify local inflammation, and further contribute to tissue destruction (7,8).

The immune response to gut microbes also involves the innate immune system, where macrophages and dendritic cells play vital roles in recognizing and responding to microbial invasion via mechanisms such as pathogen-associated molecular pattern (PAMP) recognition (9). A key regulator in this response is NOD2 (nucleotide-binding oligomerization domain 2), which detects bacterial cell wall components like muramyl dipeptide. Mutations in the NOD2 gene, encoding this protein, impair the immune system’s ability to efficiently recognize microbes, resulting in uncontrolled immune responses and chronic inflammation. Such genetic alterations underscore the critical link between pathogen recognition defects and disease progression, establishing NOD2 as a major risk factor for CD (2,9).

Other genes also contribute to CD pathogenesis. The IL-23R gene, encoding the interleukin-23 receptor, plays a role in the differentiation of Th17 cells. Mutations in IL-23R result in overactivation of Th17 cells, enhancing IL-17 production and other inflammatory cytokines, thereby fueling chronic inflammation. Additionally, polymorphisms in the ATG16L1 gene, involved in autophagy processes, have been identified as risk factors (4). Autophagy, a cellular mechanism essential for maintaining cellular homeostasis and managing pathogens, is impaired in individuals with these mutations, leading to inefficient pathogen elimination, intensified inflammation, and progression of CD (10). Single nucleotide polymorphisms (SNPs) in genes regulating immune responses also play significant roles in CD susceptibility. For example, SNPs in genes controlling T-cell differentiation, such as T-bet (regulating Th1 differentiation) and ROR-γt (regulating Th17 differentiation), can disrupt the balance between these T-cell subsets. Dysregulation of T cells leads to excessive inflammatory responses. Increased activity of Th1 and Th17 cells exacerbates intestinal tissue damage, worsening disease progression and hindering recovery (7,11).

Changes in gut microbiota, or dysbiosis, significantly contribute to CD pathogenesis. Dysbiosis, characterized by an imbalance in the composition of gut microbes, not only triggers but also aggravates inflammation. A reduction in microbial diversity leads to a loss of anti-inflammatory bacteria, while pathogenic bacteria such as *Escherichia coli* proliferate, eliciting excessive immune responses (12). Dysbiosis increases the penetration of pathogenic bacteria into the epithelial layers of the gut, further activating immune responses and worsening inflammation. Moreover, dysbiosis impairs mucosal barrier function, heightening susceptibility to inflammation (4).

In addition to immune and microbial factors, molecular regulation of adhesion molecules plays a crucial role. Adhesion molecules such as ICAM-1 and VCAM-1 facilitate immune cell recruitment to inflammation sites. In CD, elevated expression of these molecules promotes the migration of T cells, macrophages, and neutrophils into affected tissues, exacerbating inflammation and further damaging the intestinal wall (13). This process is associated with increased production of pro-inflammatory cytokines, intensifying the inflammatory state. Overall, the pathogenesis of Crohn's Disease results from complex interactions among genetic factors, immune responses, gut microbiota, and molecular regulators, culminating in chronic inflammation. Genetic mutations affecting immune response to pathogens, such as those in NOD2 and regulators of Th1 and Th17 differentiation, are pivotal for understanding disease mechanisms. Dysbiosis-induced mucosal damage is another key factor in disease progression, emphasizing the need for deeper insights into these interactions to develop targeted therapeutic strategies for CD management.

Pathophysiology and Clinical Manifestations. The pathophysiology of Crohn's Disease begins with immune dysregulation, leading to transmural inflammation in the gastrointestinal tract. This inflammation can occur at any point along the gastrointestinal tract but is most frequently found in the terminal ileum and colon. In CD, inflammation is segmental, presenting as patches or "skip lesions" separated by healthy areas (2). This feature contrasts with other inflammatory bowel diseases, such as ulcerative colitis, which affect the intestine continuously. At the tissue level, transmural inflammation causes damage to the intestinal mucosa and submucosa, resulting in intestinal wall thickening. These changes disrupt the normal structure of the intestine and impair nutrient absorption, contributing to clinical symptoms like malabsorption and diarrhea (5). Intestinal wall thickening occurs due to immune cell infiltration, angiogenesis, and plasma protein accumulation, causing swelling and bleeding. The accumulation of inflammatory cells, particularly lymphocytes, macrophages, and neutrophils, exacerbates inflammation and increases pro-inflammatory cytokine production, further worsening the condition (5,6).

The formation of non-caseating granulomas, a hallmark of CD, occurs as part of the immune response to pathogens or antigens that cannot be eliminated. These granulomas, often found in the terminal ileum, aim to contain infections or inflammation but can also cause extensive tissue damage, leading to fibrosis and strictures in the intestinal wall. This fibrosis exacerbates intestinal obstruction and reduces motility (3). Another pathophysiological hallmark of CD is the development of fistulas—abnormal channels connecting different segments of the intestine or linking the intestine to other organs such as the bladder or vagina. Fistulas form due to inflammation-induced intestinal wall damage, facilitating the spread of infection or fluids to adjacent organs. Intestinal fistulas, especially in the perianal region, are common in CD patients and may result in abscesses, peritonitis, and severe clinical symptoms (14).

Intense inflammation may also lead to intestinal perforation, often resulting in peritonitis, an inflammatory condition of the peritoneal cavity, with symptoms like severe abdominal pain, fever, and cramping. If untreated, perforation can cause life-threatening sepsis (5,6). On a microscopic level, increased mucosal permeability allows bacteria and toxins to penetrate damaged intestinal layers, further activating the immune system and worsening inflammation. This process causes systemic symptoms such as fever, fatigue, and weight loss (15). Damage to the intestinal epithelium disrupts the gut barrier, exacerbating nutrient malabsorption and leading to nutritional deficiencies commonly seen in CD patients. Over time, chronic inflammation and incomplete reparative processes may lead to stricture formation, narrowing the intestinal lumen. Strictures can obstruct intestinal content flow, causing symptoms like vomiting, bloating, and constipation. Severe obstructions often require surgical intervention to remove damaged or blocked intestinal segments (5).

The clinical manifestations of CD vary based on the location and severity of inflammation. Common symptoms include chronic diarrhea, often with blood or pus in cases of severe inflammation or secondary infection. Abdominal pain, particularly in the lower right quadrant, is another predominant complaint. Systemic symptoms like fever, fatigue, and weight loss frequently occur due to prolonged inflammation and disrupted nutrient absorption (5). Extra-intestinal manifestations are also common in CD, such as peripheral arthritis, uveitis, or erythema nodosum,

indicative of systemic immune involvement. Skin conditions like erythema nodosum, presenting as painful red nodules, are frequently observed in CD patients and associated with systemic inflammation. Additionally, there is an increased risk of kidney stones, particularly in patients with chronic diarrhea or fluid deficiencies (6).

The disease also predisposes patients to vascular complications, such as deep vein thrombosis (DVT), stemming from coagulation abnormalities linked to chronic inflammation. Changes in blood vessels, including increased permeability and clot formation, contribute to a higher risk of thromboembolic complications in CD patients (6). In summary, the pathophysiology of Crohn's Disease involves complex tissue alterations, culminating in significant organ damage and functional impairments. Clinical symptoms are influenced by the location and severity of inflammation and complications arising during disease progression. A comprehensive understanding of these tissue changes is crucial for effective management, encompassing both pharmacological and surgical interventions.

3. Conclusion

Crohn's Disease (CD) involves a complex pathogenesis characterized by dysregulated immune responses to gut microbiota, with CD4+ T cells, such as Th1 and Th17, playing pivotal roles in triggering transmural inflammation. Genetic factors, including mutations in the NOD2 and IL-23R genes, as well as disruptions in gut microbiota, also contribute significantly to disease susceptibility. The inflammatory process leads to substantial tissue damage, including the formation of non-caseating granulomas, strictures, fistulas, and intestinal perforations. Clinical manifestations, such as chronic diarrhea, abdominal pain, and weight loss, along with severe complications like abscesses and deep vein thrombosis, highlight the profound impact of CD on patients' quality of life. A deeper understanding of CD pathophysiology can pave the way for more targeted therapies and improved disease management.

4. References

1. Tian L, Yang X, Zheng Y, Peng C. The association between circulating leukocytes and inflammatory bowel disease: a two-sample Mendelian randomization study. Front Med. 2024;11(May):1–6.
2. Choudhury A, Dhillon J, Sekar A, Gupta P, Singh H, Sharma V. Differentiating gastrointestinal tuberculosis and Crohn's disease- a comprehensive review. BMC Gastroenterol [Internet]. 2023;23(1):1–19. Available from: https://doi.org/10.1186/s12876-023-02887-0
3. Saez A, Herrero-Fernandez B, Gomez-Bris R, Sánchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int J Mol Sci. 2023;24(2).
4. Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019;2019.
5. Kúsulas-delint D, González-regueiro JA, Rodríguez-aldama JC. Crohn ' s disease . Review and current concepts. 2019;(March):9–20.
6. Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY, et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc [Internet]. 2019;118(7):1083–92. Available from: https://doi.org/10.1016/j.jfma.2018.07.005
7. Chen R, Li C, Zheng J, Fan Z, Li L, Chen M, et al. Lymphocyte subsets for predicting inflammatory bowel disease progression and treatment response: a systematic review. Front Immunol. 2024;15(August):1–13.

8. Pasternak G, Chrzanowski G, Aebisher D, Myśliwiec A, Dynarowicz K, Bartusik-Aebisher D, et al. Crohn's Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review. Life. 2023;13(10).
9. De Mattos BRR, Garcia MPG, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, et al. Inflammatory bowel disease: An overview of immune mechanisms and biological treatments. Mediators Inflamm. 2015;2015.
10. Abbas AK, Litchman A h., Pillai S. Cellular and Molecular Immunology. Ninth Edit. Abbas AK, editor. Elsevier. Elsevier; 2018. 1–514 p.
11. Wu Y, Shen J. Innate Lymphoid Cells in Crohn's Disease. Front Immunol. 2020;11(November):1–12.
12. Diez-Martin E, Hernandez-Suarez L, Muñoz-Villafranca C, Martin-Souto L, Astigarraga E, Ramirez-Garcia A, et al. Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options. Int J Mol Sci. 2024;25(13).
13. Garza-Hernandez D, Sepulveda-Villegas M, Garcia-Pelaez J, Aguirre-Gamboa R, Lakatos PL, Estrada K, et al. A systematic review and functional bioinformatics analysis of genes associated with Crohn's disease identify more than 120 related genes. BMC Genomics [Internet]. 2022;23(1):1–14. Available from: https://doi.org/10.1186/s12864-022-08491-y
14. Choy MC, Visvanathan K, De Cruz P. An overview of the innate and adaptive immune system in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(1):2–13.
15. Alhendi A, Naser SA. The dual role of interleukin-6 in Crohn's disease pathophysiology. Front Immunol. 2023;14(December):1–10.